| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Top-line Data example | Tibulizumab (ZB-106) hidradenitis suppurativa (HS) | Phase 2 | — | Biologics | Dermatologic System | ||
Top-line Data example | Tibulizumab (ZB-106) hidradenitis suppurativa (HS) | Phase 2 | — | Biologics | Dermatologic System | ||
Top-line Data example | Tibulizumab (ZB-106) hidradenitis suppurativa (HS) | Phase 2 | — | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Zura Bio Limited$3.65
+0.03 (+0.83%)
D 30Pipeline Score Richly Valued Biotech · Clinical
Market Cap
414.19 M
EPS
-1.22
P/E Ratio
-
Value Trade
2.65 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
14.75 M
Operating CF
-18.92 M
Total Assets
228.64 M
Total Liabilities
11.74 M
Equity
216.90 M
D/E Ratio
12,345
-7.43 %
Week
-18.5 %
1 Month
-29.9 %
3 Month
17.84 %
6 Month
-55.28 %
5 Year
-55.28 %
All Time
Cash Data
Cash Position
225.59 M
Monthly Burn
6.31 M
Runway
34.4 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
159.96 K
52 Week Range
0.98 - 7.44
% held by Insiders
33.25 %
% held by Institutions
67.26 %
Enterprise Value
188.60 M
Total Shares
94.93 M
Short %
11.96 %
Float Shares
52.02 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D30
Pipeline Score $8M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 36%
Micro Cap (rank 580 of 905)
Percentile RankZura Bio Limited faces pipeline headwinds (30/100), with $20M risk-adjusted pipeline value, led by Tibulizumab Dose A in Hidradenitis Suppurativa (HS) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tibulizumab Dose A Monoclonal antibody | Hidradenitis Suppurativa (HS) | Phase 2 | NCT06993610 | 26% | $15M | RECRUITING | 225 | STALLED | B (64) | Apr 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZURA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ZURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZURA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZURA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ZURA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZURAZura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Zura Bio has announced the appointment of Muzammil Mustufa as Chief Business Officer. This expansion of the leadership team is aimed at enhancing the company's strategic direction and growth potential. Mustufa's experience is expected to contribute positively to Zura Bio's objectives.
Read more →ZURAZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Limited reported its financial results for Q1 2026, highlighting a strengthened balance sheet with $225.6 million in cash. The company is advancing two Phase 2 studies for its lead product, tibulizumab, with anticipated data readouts later this year and in 2027. Despite an increase in net loss and R&D expenses, Zura's leadership changes and ongoing clinical trials position it favorably in the market.
Read more →ZURAZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This move is part of their compliance with regulatory requirements, although specific details about the grants were not disclosed in the article.
Read more →ZURAZura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Zura Bio Limited reported its financial results for the year ending December 31, 2025, highlighting significant progress in its Phase 2 clinical programs. The company raised $144 million to strengthen its balance sheet and is focused on advancing its lead candidate, tibulizumab. Anticipated data readouts from ongoing studies are expected in late 2026 and early 2027, positioning Zura for potential growth despite increasing net losses.
Read more →ZURAZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Zura Bio announced that its Phase 2 TibuSURE study design will be presented at the Systemic Sclerosis World Congress in March 2026. The study evaluates tibulizumab, a bispecific antibody targeting IL-17A and BAFF, in adults with systemic sclerosis. The trial aims to enroll 80 participants and will assess the drug's efficacy and safety over 24 weeks, with results expected in 2027.
Read more →ZURAZura Bio to Participate in Upcoming Investor Conferences
Zura Bio Limited will participate in two upcoming investor conferences in Miami, FL. The management team will engage in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026, followed by investor meetings at the Jefferies Biotech on the Beach Summit on March 11, 2026. The company is focused on developing novel therapies for autoimmune and inflammatory diseases.
Read more →ZURAZura Bio to Participate in Upcoming March 2026 Investor Conferences
Zura Bio Limited, a clinical-stage biotechnology firm, announced its participation in upcoming investor conferences, including the Leerink Global Healthcare Conference and the Jefferies Biotech on the Beach Summit. The company's management will engage with investors to discuss its innovative pipeline, which focuses on treatments for autoimmune and inflammatory diseases. Zura's lead candidate, tibulizumab, is currently in Phase 2 studies.
Read more →ZURAZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Zura Bio Limited has successfully closed a public offering of Class A ordinary shares and pre-funded warrants, raising approximately $144 million. The offering included 21.2 million shares priced at $6.25 each, along with additional shares sold due to underwriters' full exercise of their purchase option. This funding will support Zura's clinical-stage development of novel therapies for autoimmune and inflammatory diseases.
Read more →ZURAZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Limited has announced the pricing of its public offering of 18.2 million Class A ordinary shares at $6.25 each, aiming to raise $125 million. The offering includes pre-funded warrants for additional shares and is set to close on February 26, 2026, pending customary conditions. The funds will support Zura's clinical development of therapies for autoimmune diseases.
Read more →ZURAZura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
Zura Bio Limited has appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. Both appointees bring significant experience in immunology and drug development, which will support Zura's Phase 2 programs and growth opportunities. Neil Graham will step down from the Board on the same date.
Read more →ZURAZura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Zura Bio Limited will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company's senior leadership will engage in a fireside chat and conduct one-on-one investor meetings. Zura is focused on developing novel therapies for autoimmune and inflammatory diseases, with several candidates in various stages of clinical trials.
Read more →ZURAZura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
Zura Bio Limited has appointed Dr. Sandeep Kulkarni as its new CEO, effective January 21, 2026. He succeeds Kim Davis, who served as Interim CEO after Robert Lisicki's resignation. Dr. Kulkarni brings over two decades of experience in biotechnology and medicine, and he aims to lead Zura through critical upcoming clinical readouts.
Read more →Competitive Position
How ZURA ranks across every disease it competes inCompetitive Position is a premium feature
See how ZURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial